Abstract
Androgen receptor (AR) is a key player in prostate cancer development and progression. Here we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to identify components of the AR transcriptional complex. In total, 66 known and novel AR interactors were identified in the presence of synthetic androgen, most of which were critical for AR-driven prostate cancer cell proliferation. A subset of AR interactors required for LNCaP proliferation were profiled using chromatin immunoprecipitation assays followed by sequencing, identifying distinct genomic subcomplexes of AR interaction partners. Interestingly, three major subgroups of genomic subcomplexes were identified, where selective gain of function for AR genomic action in tumorigenesis was found, dictated by FOXA1 and HOXB13. In summary, by combining proteomic and genomic approaches we reveal subclasses of AR transcriptional complexes, differentiating normal AR behavior from the oncogenic state. In this process, the expression of AR interactors has key roles by reprogramming the AR cistrome and interactome in a genomic location-specific manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR . Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007; 21: 2005–2017.
Heemers HV, Tindall DJ . Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778–808.
Huang ZQ, Li J, Sachs LM, Cole PA, Wong J . A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription. EMBO J 2003; 22: 2146–2155.
Yang YA, Yu J . Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis 2015; 2: 144–151.
Jozwik KM, Carroll JS . Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 2012; 12: 381–385.
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443–454.
Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011; 474: 390–394.
Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol 2011; 31: 4648–4662.
van der Steen T, Tindall DJ, Huang H . Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 2013; 14: 14833–14859.
Cross DS, Burmester JK . Functional characterization of the HOXB13 promoter region. Med Oncol 2008; 25: 287–293.
Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 2009; 36: 405–416.
Kim SD, Park RY, Kim YR, Kim IJ, Kang TW, Nam KI et al. HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression. Anat Cell Biol 2010; 43: 284–293.
Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet 2015; 47: 1346–1351.
Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G et al. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med 2015; 7: 1450–1464.
Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J 2015; 34: 502–516.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697–1708.
Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J et al. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res 2016; 14: 324–331.
Etani T, Suzuki T, Naiki T, Naiki-Ito A, Ando R, Iida K et al. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget 2015; 6: 2865–2878.
Hsiao JJ, Ng BH, Smits MM, Martinez HD, Jasavala RJ, Hinkson IV et al. Research resource: androgen receptor activity is regulated through the mobilization of cell surface receptor networks. Mol Endocrinol 2015; 29: 1195–1218.
Hsiao JJ, Smits MM, Ng BH, Lee J, Wright ME . Discovery proteomics identifies a molecular link between the coatomer protein complex I and androgen receptor-dependent transcription. J Biol Chem 2016; 291: 18818–18842.
Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK et al. Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Mol Cell Proteomics 2007; 6: 252–271.
Mooslehner KA, Davies JD, Hughes IA . A cell model for conditional profiling of androgen-receptor-interacting proteins. Int J Endocrinol 2012; 2012: 381824.
Comuzzi B, Sadar MD . Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cell Sci 2006; 3: 61–81.
Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B et al. c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks. EBioMedicine 2017; 18: 83–93..
Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I et al. Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. Cancer Res 2017; 77: 3417–3430..
Mohammed H, Taylor C, Brown GD, Papachristou EK, Carroll JS, D'Santos CS . Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat Protoc 2016; 11: 316–326.
Fang Y, Fliss AE, Robins DM, Caplan AJ . Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996; 271: 28697–28702.
Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci USA 2017; 114: E5207–E5215.
Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007; 8: 871–878.
Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380–392.
Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A et al. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 2008; 3: e3645.
Jangal M, Couture JP, Bianco S, Magnani L, Mohammed H, Gevry N . The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor alpha target genes. Nucleic Acids Res 2014; 42: 11339–11348.
Abrink M, Ortiz JA, Mark C, Sanchez C, Looman C, Hellman L et al. Conserved interaction between distinct Kruppel-associated box domains and the transcriptional intermediary factor 1 beta. Proc Natl Acad Sci USA 2001; 98: 1422–1426.
Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG et al. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 1996; 10: 2067–2078.
Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013; 3: 1254–1271.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668–675.
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013; 3: 1245–1253.
Schiewer MJ, Knudsen KE . Linking DNA damage and hormone signaling pathways in cancer. Trends Endocrinol Metab 2016; 27: 216–225.
Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012; 2: 1134–1149.
Marshall TW, Link KA, Petre-Draviam CE, Knudsen KE . Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem 2003; 278: 30605–30613.
G Hendrickson D, Kelley DR, Tenen D, Bernstein B, Rinn JL . Widespread RNA binding by chromatin-associated proteins. Genome Biol 2016; 17: 28.
Bose DA, Donahue G, Reinberg D, Shiekhattar R, Bonasio R, Berger SL . RNA binding to CBP stimulates histone acetylation and transcription. Cell 2017; 168: 135–149 e122.
Beltran M, Yates CM, Skalska L, Dawson M, Reis FP, Viiri K et al. The interaction of PRC2 with RNA or chromatin is mutually antagonistic. Genome Res 2016; 26: 896–907.
Fan S, Goto K, Chen G, Morinaga H, Nomura M, Okabe T et al. Identification of the functional domains of ANT-1, a novel coactivator of the androgen receptor. Biochem Biophys Res Commun 2006; 341: 192–201.
Goto K, Zhao Y, Saito M, Tomura A, Morinaga H, Nomura M et al. Activation function-1 domain of androgen receptor contributes to the interaction between two distinct subnuclear compartments. J Steroid Biochem Mol Biol 2003; 85: 201–208.
Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998; 18: 4471–4487.
Imberg-Kazdan K, Ha S, Greenfield A, Poultney CS, Bonneau R, Logan SK et al. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res 2013; 23: 581–591.
Van Tilborgh N, Spans L, Helsen C, Clinckemalie L, Dubois V, Lerut E et al. The transcription intermediary factor 1beta coactivates the androgen receptor. J Endocrinol Invest 2013; 36: 699–706.
Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J 1996; 15: 6701–6715.
Zhou XE, Suino-Powell KM, Li J, He Y, Mackeigan JP, Melcher K et al. Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. J Biol Chem 2010; 285: 9161–9171.
Vander Griend DJ, Litvinov IV, Isaacs JT . Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci 2014; 10: 627–642.
Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30: 3962–3976.
Jin HJ, Zhao JC, Wu L, Kim J, Yu J . Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun 2014; 5: 3972.
van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996; 149: 1055–1062.
van Weerden WM, Bangma C, de Wit R . Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 2009; 100: 13–18.
van Steenbrugge GJ, Groen M, de Jong FH, Schroeder FH . The use of steroid-containing silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles. Prostate 1984; 5: 639–647.
Ameziane N, May P, Haitjema A, van de Vrugt HJ, van Rossum-Fikkert SE, Ristic D et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat Commun 2015; 6: 8829.
Acknowledgements
We thank the NKI Genomics Core Facility for Illumina sequencing and bioinformatic support. SS is supported by Movember (NKI01). We thank Corrina MA de Ridder for dedicated maintenance and biobanking of the PDX models. WZ is supported by a KWF Dutch Cancer Society/Alpe d’HuZes Bas Mulder Award (NKI 2014-6711) and a VIDI grant (016.156.401) from The Netherlands Organisation for Scientific Research (NWO). This work is further supported by NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands, Proteins@Work (184.032.201) to OBB and AFMA and a VIDI grant (723.012.102) to AFMA.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Stelloo, S., Nevedomskaya, E., Kim, Y. et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene 37, 313–322 (2018). https://doi.org/10.1038/onc.2017.330
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2017.330
This article is cited by
-
The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer
Genome Biology (2024)
-
TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer
Oncogene (2023)
-
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer
Oncogene (2023)
-
Ribosome impairment regulates intestinal stem cell identity via ZAKÉ‘ activation
Nature Communications (2022)
-
Dynamic nucleosome landscape elicits a noncanonical GATA2 pioneer model
Nature Communications (2022)